HARROW, INC.
HROWHarrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee. Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a $20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a $20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 million Series A financing.
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 10, 2026
27dMarket Overview
Stock performance and key metrics
1 upcoming, 1 past
No drugs found in this phase.
Full breakdown — the signals behind the verdict
Frequently asked questions
When is HARROW, INC.'s next FDA catalyst?→
HARROW, INC.'s (HROW) next tracked catalyst is a Regulatory expected July 1, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track HROW biotech catalysts?→
Add HROW to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow HARROW, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.